Prolonged survival of a patient with brain melanoma metastasis treated with BRAF and MEK inhibitors combination therapy

G Ital Dermatol Venereol. 2020 Apr;155(2):245-247. doi: 10.23736/S0392-0488.18.05990-4. Epub 2018 May 10.

Authors

Giulia Spallone¹, Virginia Garofalo², Eliseo Picchi³, Rossella Pitocco², Federico Bianchi⁴, Alessandra Ventura², Riccardo Santoni⁵, Luca Bianchi²

Affiliations

¹ Department of Dermatology, Tor Vergata University, Rome, Italy - giuliaspallone@hotmail.it.
² Department of Dermatology, Tor Vergata University, Rome, Italy.
³ Department of Radiology and Medical Imaging, Tor Vergata University, Rome, Italy.
⁴ Department of Radiotherapy, Tor Vergata University, Rome, Italy.
⁵ Department of Neurosurgery, Tor Vergata University, Rome, Italy.

PMID: 29747484
DOI: 10.23736/S0392-0488.18.05990-4

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Brain Neoplasms / drug therapy*
Brain Neoplasms / pathology
Brain Neoplasms / secondary
Humans
Male
Melanoma / drug therapy*
Melanoma / pathology
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Survival Rate

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases